Re­se­arch | 22 Ok­to­ber 2026 16​:00

Ori­gi­nal-Re­se­arch: Ad­van­ced Block­chain AG – from GBC AG

22.10.2026 / 16​:00 CET/CEST
Dis­se­mi­na­ti­on of a Re­se­arch, trans­mit­ted by EQS News– a ser­vice of EQS Group.
The is­suer is so­le­ly re­spon­si­ble for the con­tent of this re­se­arch. The re­sult of this re­se­arch does not con­sti­tu­te in­vest­ment ad­vice or an in­vi­ta­ti­on to con­clude cer­tain stock ex­ch­an­ge tran­sac­tions.


Clas­si­fi­ca­ti­on of GBC AG to Ad­van­ced Block­chain AG

Com­pa­ny Name: Ad­van­ced Block­chain AG
ISIN: DE000A0M93V6
Re­ason for the re­se­arch: Re­se­arch Note
Re­com­men­da­ti­on: Buy
Tar­get pri­ce: 2.00
Tar­get pri­ce on sight of: 31.12.2027
Last ra­ting ch­an­ge:
Ana­lyst: Mat­thi­as Greif­fen­ber­ger, Cos­min Fil­ker

Pro­gress at Po­ly­mer, peaq and Si­len­cio un­der­pins the in­vest­ment the­sis

Re­cent pro­gress across Ad­van­ced Block­chain AG’s in­vest­ment port­fo­lio sup­ports the com​pany’s long-term in­vest­ment the­sis. In ear­ly Oc­to­ber, Po­ly­mer re­por­ted cu­mu­la­ti­ve cross-chain trans­fer vo­lu­me of US$3.74 bil­li­on, while month­ly vo­lu­me in­creased from ap­pro­xi­m­ate­ly US$100 mil­li­on in De­cem­ber 2025 to more than US$500 mil­li­on in Sep­tem­ber 2026. At peaq, the col­la­bo­ra­ti­on with Doos­an Ro­bo­tics high­lights the po­ten­ti­al for in­dus­tri­al ap­pli­ca­ti­ons. Si­len­cio is al­re­a­dy de­mons­t­ra­ting com­mer­cial pro­gress: re­ve­nue from its voice AI busi­ness in­creased from ap­pro­xi­m­ate­ly US$0.10 mil­li­on in Q1 to US$0.30 mil­li­on in Q2 2026. The­se de­ve­lo­p­ments could im­pro­ve the eco­no­mic pro­s­pects of AB​A​G’s equi­ty in­vest­ments and to­ken rights.

The com­pa­ny is also ad­van­cing its ope­ra­tio­nal rea­lignment un­der ABAG 2.0. Fin­Pro is to be re­ac­ti­va­ted as a to­ke­nisa­ti­on plat­form, com­ple­men­ted by sel­ec­ted in­vest­ment ac­ti­vi­ties. Pro­ject and bud­get plan­ning for ABX Ana­ly­tics has been com­ple­ted, and fun­ding ap­pli­ca­ti­ons have been sub­mit­ted. Fol­lo­wing a suc­cessful fe­a­si­bi­li­ty pha­se, Nut­ri­vo is de­ve­lo­ping its first usable pro­duct ver­si­on. The­se in­itia­ti­ves of­fer ad­di­tio­nal re­ve­nue op­por­tu­ni­ties, alt­hough their eco­no­mic con­tri­bu­ti­on will de­pend on suc­cessful com­mer­cia­li­sa­ti­on.

The pa­rent com​pany’s half-year re­sults con­ti­nue to re­flect chal­len­ging ear­nings con­di­ti­ons. Re­ve­nue de­cli­ned by 33.8% to €89.4k (pre­vious year: €135.0k). Hig­her per­son­nel ex­pen­ses and le­gal and ad­vi­so­ry cos­ts weig­hed on pro­fi­ta­bi­li­ty. EBITDA de­te­rio­ra­ted to -€661.3k (pre­vious year: -€539.4k), while the half-year net loss wi­den­ed to -€703.5k (pre­vious year: -€586.1k). In­sour­cing ac­ti­vi­ties pre­vious­ly per­for­med ex­tern­al­ly is ex­pec­ted to ge­ne­ra­te fu­ture sa­vings, alt­hough the­se be­ne­fits are not yet evi­dent in the re­por­ted fi­gu­res.

Equi­ty de­cli­ned from €5.40 mil­li­on at year-end 2025 to €4.69 mil­li­on, with the equi­ty ra­tio fal­ling from 56.6% to 50.3%. The pa­rent com​pany’s cash ba­lan­ce de­creased from €104.9k to €1.9k. The­se fi­gu­res re­la­te to its stan­da­lo­ne fi­nan­cial state­ments and do not pro­vi­de a com­ple­te as­sess­ment of group li­qui­di­ty. A sub­stan­ti­al part of the in­vest­ment port­fo­lio is held by In­c­re­du­lous Labs. Fun­ding the­r­e­fo­re re­mains de­pen­dent on available port­fo­lio pro­ceeds, in­tra-group pay­ments and, whe­re ne­ces­sa­ry, ad­di­tio­nal fi­nan­cing.

We con­ti­nue to va­lue the group using an ad­jus­ted NAV ap­proach in­cor­po­ra­ting a par­ti­al re­co­very in sel­ec­ted equi­ty in­vest­ments and to­ken rights. From the as­su­med gross as­set va­lue of €14.70 mil­li­on, we de­duct €5.10 mil­li­on for lia­bi­li­ties and fi­nan­cing risks and €1.49 mil­li­on for the pre­sent va­lue of fu­ture net hol­ding cos­ts. This re­sults in an ad­jus­ted NAV of €8.11 mil­li­on. The re­du­ced hol­ding-cost as­sump­ti­on re­qui­res sus­tainable sa­vings and a lower net cost bur­den. Ba­sed on the­se as­sump­ti­ons, we rei­te­ra­te our BUY ra­ting with a roun­ded pri­ce tar­get of €2.00. Va­lue rea­li­sa­ti­on re­mains ma­te­ri­al­ly de­pen­dent on to­ken mar­kets, suc­cessful port­fo­lio mo­ne­ti­sa­ti­on and the im­ple­men­ta­ti­on of ABAG 2.0.

You can down­load the re­se­arch here: 20261022_Note_ABAG_en

Cont­act for ques­ti­ons:
GBC AG
Hal­der­stra­ße 27
86150 Augs­burg
0821⁄241133 0
research@​gbc-​ag.​de
++++++++++++++++
Of­fen­le­gung mög­li­cher In­ter­es­sens­kon­flik­te nach § 85 WpHG und Art. 20 MAR Beim oben ana­ly­sier­ten Un­ter­neh­men ist fol­gen­der mög­li­cher In­ter­es­sen­kon­flikt ge­ge­ben: (5a,11); Ei­nen Ka­ta­log mög­li­cher In­ter­es­sen­kon­flik­te fin­den Sie un­ter: https://​www​.gbc​-ag​.de/de​/Offenlegung.htm

Hin­weis zu Is­suer-Spon­so­red Re­se­arch: Vor­lie­gen­de Re­se­arch­stu­die ist Is­suer-Spon­so­red Re­se­arch und wur­de in Über­ein­stim­mung mit dem EU-Ver­hal­tens­ko­dex (EU Code of Con­duct) für Is­suer-Spon­so­red Re­se­arch er­stellt.
+++++++++++++++
Com­ple­ti­on: 22 Oc­to­ber 2026 (3.00 pm)
First dis­tri­bu­ti­on: 22 Oc­to­ber 2026 (4.00 pm)

Ori­gi­nal-Re­se­arch: Fin­exi­ty AG (by GBC AG): Buy

GBC AG
Hal­der­stra­ße 27
86150 Augs­burg

Te­le­fon: +49 821 241133–0
E‑mail: office(@)gbc-ag.de